Discussion with MindMed CEO Rob Barrow and Paul Matteis

MindMed CEO Rob Barrow discusses clinical development and regulatory strategy for MM120, an orally disintegrating tablet formulation of LSD, targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD). Phase 2 and Phase 3 trial data, including the Voyage and Panorama studies, demonstrate statistically significant efficacy with strong effect sizes around 0.81. High-dose 100 microgram treatments show clear superiority over lower doses and placebo in long-term symptom reduction. Regulatory interactions with the FDA focus on study design, functional unblinding controls, and the inclusion of mid-dose arms. Commercialization strategies explore interventional psychiatry clinic expansion, CPT coding, and reimbursement frameworks.